Plain-English translation of NCT07236463 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
When sepsis (a serious infection) damages the kidneys severely, patients need dialysis — a machine that filters waste from their blood. This trial is testing whether MEX-CD1, an iron-binding compound added to the dialysis fluid, can help remove excess iron from the blood more effectively. Excess iron may contribute to organ damage during sepsis, so reducing it might help patients recover better.
Sepsis-associated kidney failure has no specific treatment beyond kidney support, and patients often have poor outcomes. Research suggests that excess iron in the blood worsens organ damage during sepsis, so removing it during dialysis could potentially improve survival and long-term health.
You likely qualify if…
You likely don't qualify if…
You will receive two consecutive 24-hour dialysis sessions while admitted to the intensive care unit. One session will use standard dialysis fluid, and the other will use dialysis fluid with the experimental iron-binding compound added to it. The order will be randomly assigned — some participants will receive the experimental treatment first, others the standard treatment first. Because you serve as your own control, this helps doctors see whether the new treatment truly makes a difference for you.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
France